Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

PASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.


'/>"/>

SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that the independent Data Safety ... on-going MAESTRO-03 U.S. pivotal phase III,clinical trial of ... and,recommended that the trial continue., This was ...
... Bionovo Inc.,(Nasdaq: BNVI ) will present findings on ... BN107 and BN108 at the American Association of,Cancer Research ... in San,Diego, CA, April 12 - 16, 2008., ... cell,apoptosis (cell death) induced by BN107 and BN108. As ...
... ST. JOSEPH, Mich., April 15 GeneGo, Inc., ... The Scripps,Translational Science Institute has joined the MetaMiner ... build the first systems,biology and pathway analysis platform ... will vote on deliverables that will include,disease specific ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... that can be found in both unprocessed and processed ... Denmark have been infected with Listeria from ... The bacterium is notoriously difficult to fight because it ... in its surroundings, says Associate Professor Birgitte Kallipolitis, University ... of Biochemistry and Molecular Biology, she has published a ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... energy produced by cars, machines, and industry around the world ... but researchers have found a new way to make "thermoelectric" ... amounts of energy. And it,s based on a device ... Chemists at Oregon State University have discovered that simple ...
... team has turned their newly developed 3-D microscope technology ... use. U of A engineering professor Dileepan ... system called Virtual Reflected-Light Microscopy. The technology consists of ... that moves the objects being photographed and software programs ...
... Paul Kenis and James Slauch have been named ... university,s most talented teachers, scholars and researchers. Kenis, ... in the field of micro fluidics and the development ... health. These tools include the creation of evaporation-based ...
Cached Biology News:Microwave ovens a key to energy production from wasted heat 2Microwave ovens a key to energy production from wasted heat 3University of Illinois faculty members named University Scholars 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: